Published on
March 20, 2024
- 17:13 GMT
HELIXNANO’S SUBSIDIARY, HELIXNANO AUSTRALIA, RECEIVES HREC APPROVAL TO INITIATE A PHASE 1 CLINICAL TRIAL
First participants anticipated to be dosed with HN-0001, a next-generation COVID19 mRNA vaccine candidate, in April 2024 BOSTON, MA, UNITED STATES, March 20, 2024 /EINPresswire.com/ -- HelixNano, a leading biotechnology startup developing next- …
Distribution channels:
Healthcare & Pharmaceuticals Industry
...
